Catalent, which carved out its place in gene therapies with its $1.2 billion deal for Paragon Services, is adding another serving to its plate. It will pay $315 million for Masthercell Global, a Belgium-based cell and gene therapy CDMO with operations in Europe and the US. Source: Fierce Pharma 3/2/2020